Früherkennung und
Früherkennung und Diagnose von Herz-Kreislauf-Erkrankungen:Ein Manifest für Veränderung47. Cleveland Clinic. nd. B-type Natriuretic Peptide (BNP) Test. Available from: https://my.clevelandclinic.org/health/diagnostics/22629-b-type-natriuretic-peptide [Accessed 04/12/2023]48. Taylor C, Lay-Flurrie S, Ordóñez-Mena J, et al. 2022. Natriuretic peptide level at heart failure diagnosis and risk ofhospitalisation and death in England 2004-2018. Heart 108(7): 543-4949. European Heart Network, European Society of Cardiology. 2020. Fighting cardiovascular disease – a blueprint for EU action.Brussels: European Heart Network50. Herbert B, Johnson A, Paasche-Orlow M, et al. 2021. Disparities in Reporting a History of Cardiovascular Disease AmongAdults With Limited English Proficiency and Angina. JAMA Network Open 4(12): 10.1001/jamanetworkopen.2021.3878051. Hossain M, Chew-Graham C, Sowden E, et al. 2022. Challenges in the management of people with heart failure withpreserved ejection fraction (HFpEF) in primary care: A qualitative study of general practitioner perspectives. Chronic Illness18(2): 410-2552. Soljak M, Samarasundera E, Indulkar T, et al. 2011. Variations in cardiovascular disease under-diagnosis in England: nationalcross-sectional spatial analysis. BMC Cardiovascular Disorders 11: 10.1186/471-2261-11-1253. Saner H, van der Velde E. 2016. eHealth in cardiovascular medicine: A clinical update. European Journal of PreventiveCardiology 23(2 suppl): 5-1254. Chiou Y-A, Hung C-L, Lin S-F. 2021. AI-Assisted Echocardiographic Prescreening of Heart Failure With Preserved EjectionFraction on the Basis of Intrabeat Dynamics. JACC: Cardiovascular Imaging 14(11): 2091-10455. Muldoon L, Hogg W, Levitt M. 2006. Primary care (PC) and primary health care (PHC). What is the difference? CanadianJournal of Public Health 97(5): 409-1156. Joshi R, Thrift A, Smith C, et al. 2018. Task-shifting for cardiovascular risk factor management: lessons from the Global Alliancefor Chronic Diseases. BMJ Global Health, 3(Suppl 3): 10.1136/bmjgh-2018-00109257. European Heart Network, European Society of Cardiology, ERA-CVD. 2019. Challenges and opportunities for cardiovasculardisease research: Strategic research agenda for cardiovascular diseases (SRA-CVD). Koeln: German Aerospace CenterDeutsches Zentrum für Luft und Raumfahrt DRL58. Van Norman G. 2017. Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: BeyondEROOM’s Law. JACC: Basic to Translational Science 2(5): 613-2559. Ballreich J, Gross C, Powe N, et al. 2021. Allocation of National Institutes of Health Funding by Disease Category in 2008 and2019. JAMA Network Open 4(1): 10.1001/jamanetworkopen.2020.3489060. Stockmann C, Hersh A, Sherwin C, et al. 2014. Alignment of United States funding for cardiovascular disease research withdeaths, years of life lost, and hospitalizations. International Journal of Cardiology 172(1): e19-e2161. National Center for Health Statistics. 2021. Data brief 427. Mortality in the United States, 2020. Maryland: National Center forHealth Statistics62. Centers for Disease Control and Prevention. U.S. cancer statistics breast cancer stat bite. Available from: https://www.cdc.gov/cancer/uscs/about/stat-bites/stat-bite-breast.htm [Accessed 13/02/2024]63. MacArthur J, Yong G, Dweck M, et al. 2023. Cardiovascular imaging research priorities. Open Heart 10: 10.1136/openhrt-2023-00237864. Sweeney T, Quispe R, Das T, et al. 2021. The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention ofAtherosclerotic Cardiovascular Disease: a Review. Expert Review of Precision Medicine and Drug Development 6(4): 247-5865. Isselbacher E, Preventza O, Hamilton Black J, et al. 2022. 2022 ACC/AHA Guideline for the diagnosis and management ofaortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on ClinicalPractice Guidelines. Circulation 146(24): e334–e48266. Arbelo E, Protonotarios A, Gimeno J, et al. 2023. 2023 ESC Guidelines for the management of cardiomyopathies: Developedby the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) European HeartJournal 44(37): 3503-62667. Karnad A, Harding E, Farrington-Douglas J, et al. 2022. Making the case for political urgency in cardiovascular disease.Thought Leadership Forum on Cardiovascular Disease discussion paper. London: The Health Policy Partnership68. Su P-F, Sie F-C, Yang C-T, et al. 2020. Association of ambient air pollution with cardiovascular disease risks in people with type2 diabetes: a Bayesian spatial survival analysis. Environmental Health 19(1): 10.1186/s12940-020-00664-028
GLOBAL HEART HUB69. European Society of Cardiology. 2021. Closing the gaps in the cardiovascular care of women. Sophia Antipolis: EuropeanSociety of Cardiology70. Daponte-Codina A, Knox E, Mateo-Rodriguez I, et al. 2022. Gender and social inequalities in awareness of coronaryartery disease in European countries. International Journal of Environmental Research and Public Health 19(3): 10.3390/ijerph1903138871. Daugherty S, Blair I, Havranek E, et al. 2017. Implicit gender bias and the use of cardiovascular tests among cardiologists.Journal of the American Heart Association 6(12): 10.1161/JAHA.117.00687272. Anagnostis P, Lambrinoudaki I, Stevenson J, et al. 2022. Menopause-associated risk of cardiovascular disease. EndocrineConnections 11(4): 10.1530/EC-21-053773. Mullachery P, Vela E, Cleries M, et al. 2022. Inequalities by income in the prevalence of cardiovascular disease and its riskfactors in the adult population of Catalonia. Journal of the American Heart Association 11(17): 10.1161/JAHA.122.02658774. Niakouei A, Tehrani M, Fulton L. 2020. Health Disparities and Cardiovascular Disease. Healthcare (Basel) 8(1): 10.3390/healthcare801006575. Stoner L, Stoner K, Young J, et al. 2012. Preventing a cardiovascular disease epidemic among indigenous populations throughlifestyle changes. International Journal of Preventative Medicine 3(4): 230-4076. Holman D, Salway S, Bell A, et al. 2021. Can intersectionality help with understanding and tackling health inequalities?Perspectives of professional stakeholders. Health Research Policy and Systems 19(1): 10.1186/s12961-021-00742-w77. Post W, Watson K, Hansen S, et al. 2022. Racial and Ethnic Differences in All-Cause and Cardiovascular Disease Mortality: TheMESA Study. Circulation 146(3): 229-3978. International Longevity Centre UK. 2024. Holding us back? Tackling inequalities in the detection and treatment of structuralheart disease in Europe. London: International Longevity Centre UK79. Ahmed Y, van Bakel P, Hou H, et al. 2023. Racial and ethnic disparities in diagnosis, management and outcomes of aorticstenosis in the Medicare population. PLoS One 18(4): 10.1371/journal.pone.028181180. World Health Organization. 2010 Global status report on noncommunicable diseases. Gevena: World Health Organization81. Wurie H, Capuccio F. 2012. Cardiovascular disease in low- and middle-income countries: an urgent priority. Ethnicity & Health17(6): 543-5082. Minja N, Nakagaayi D, Aliku T, et al. 2022. Cardiovascular diseases in Africa in the twenty-first century: Gaps and prioritiesgoing forward. Frontiers in Cardiovascular Medicine 9: 10.3389/fcvm.2022.100833529
